Clinical pharmacology in neonates and young infants: The benefit of a population-tailored approach

2012

Clinical pharmacology in neonates and young infants

The benefit of a population-tailored approach

Additional Metadata
Keywords	biomarker, developmental pharmacology, infant, neonate, pharmacodynamics, pharmacokinetics
Persistent URL	doi.org/10.1586/ecp.11.65, hdl.handle.net/1765/31998
Journal	Expert Review of Clinical Pharmacology
Grant	This work was funded by the European Commission 7th Framework Programme; grant id fp7/223614 - Evaluation of antibiotics (ciprofloxacin and fluconazole) for the treatment of infections in preterm and term neonates (TINN), This work was funded by the European Commission 7th Framework Programme; grant id fp7/260908 - Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonates (TINN2), This work was funded by the European Commission 7th Framework Programme; grant id fp7/223060 - Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia (NEUROSIS)
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	van den Anker, J., & Allegaert, K. (2012). Clinical pharmacology in neonates and young infants: The benefit of a population-tailored approach. Expert Review of Clinical Pharmacology (Vol. 5, pp. 5–8). doi:10.1586/ecp.11.65